How has FASLODEX been studied?
FASLODEX was evaluated in two international clinical trials involving a total of 851 postmenopausal women with metastatic breast cancer whose disease had returned or progressed following previous treatment with an antiestrogen, which was usually tamoxifen. The women in the studies were randomly assigned to receive either FASLODEX or anastrozole, another hormonal breast cancer treatment. These trials established the safety and effectiveness of FASLODEX in this setting. The results showed that FASLODEX was effective when tamoxifen no longer worked.
